Illinois Municipal Retirement Fund Sells 33,535 Shares of Boston Scientific Corporation $BSX

Illinois Municipal Retirement Fund lowered its position in Boston Scientific Corporation (NYSE:BSX) by 15.4% during the 2nd quarter, HoldingsChannel reports. The firm owned 183,623 shares of the medical equipment provider’s stock after selling 33,535 shares during the period. Illinois Municipal Retirement Fund’s holdings in Boston Scientific were worth $19,723,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after acquiring an additional 1,697,945 shares during the last quarter. Invesco Ltd. lifted its position in Boston Scientific by 5.3% during the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock valued at $1,677,124,000 after purchasing an additional 834,274 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Boston Scientific by 10.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after buying an additional 1,383,524 shares in the last quarter. Amundi raised its position in shares of Boston Scientific by 2.6% during the 1st quarter. Amundi now owns 12,308,715 shares of the medical equipment provider’s stock valued at $1,212,408,000 after buying an additional 311,034 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Boston Scientific by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider’s stock worth $1,139,938,000 after acquiring an additional 460,580 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 1.0%

Shares of NYSE:BSX opened at $100.05 on Monday. The stock’s 50-day moving average is $100.09 and its 200 day moving average is $102.53. The company has a market cap of $148.32 billion, a PE ratio of 53.50, a P/E/G ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business’s revenue was up 20.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 175,782 shares of company stock valued at $17,742,314. Corporate insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $121.00 price target on shares of Boston Scientific in a research report on Friday, October 17th. Royal Bank Of Canada restated an “outperform” rating and issued a $125.00 target price on shares of Boston Scientific in a research report on Monday, September 29th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $124.00 target price on shares of Boston Scientific in a research note on Wednesday, October 22nd. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Finally, Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their target price for the company from $118.00 to $125.00 in a report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $123.77.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.